Twist Bioscience (NASDAQ:TWST – Get Free Report) was upgraded by stock analysts at Canaccord Genuity Group to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.
Other equities research analysts also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. TD Cowen set a $89.00 price objective on shares of Twist Bioscience in a research note on Monday. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research report on Monday. Leerink Partners set a $80.00 target price on shares of Twist Bioscience in a research note on Friday, May 22nd. Finally, Barclays increased their price target on Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and a consensus target price of $71.60.
Read Our Latest Research Report on TWST
Twist Bioscience Price Performance
Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The business had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period last year, the business earned ($0.66) earnings per share. On average, sell-side analysts expect that Twist Bioscience will post -2.02 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Adam Laponis sold 4,000 shares of Twist Bioscience stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $60.00, for a total transaction of $240,000.00. Following the sale, the chief financial officer directly owned 118,694 shares in the company, valued at $7,121,640. This trade represents a 3.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa A. Starovasnik sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the sale, the director directly owned 25,722 shares in the company, valued at $1,311,822. The trade was a 3.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 33,170 shares of company stock worth $1,948,964 over the last quarter. 3.08% of the stock is currently owned by corporate insiders.
Institutional Trading of Twist Bioscience
A number of institutional investors and hedge funds have recently bought and sold shares of TWST. Western Wealth Management LLC acquired a new stake in Twist Bioscience in the first quarter valued at $31,000. Strs Ohio acquired a new position in Twist Bioscience during the 1st quarter worth about $33,000. PNC Financial Services Group Inc. grew its position in shares of Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after buying an additional 453 shares during the last quarter. Quarry LP bought a new stake in shares of Twist Bioscience in the 3rd quarter valued at about $28,000. Finally, Strategic Advocates LLC increased its stake in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares during the period.
About Twist Bioscience
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
- Five stocks we like better than Twist Bioscience
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
